Assignee
ENZO THERAPEUTICS INC
US·21 granted patents·17 pending applications·196 citations·filing 1995–2021
Top patents by PatentIndex Score
38 records- 0196US9388121B2Sphingosine kinase type 1 inhibitorsENZO THERAPEUTICS INC·Filed 2012·Granted Jul 12, 2016·16 cites·12 claims
- 0295US10456370B2Sphingosine kinase type 1 inhibitors and uses thereofENZO THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·4 cites·9 claims
- 0395US10166204B2Sphingosine kinase type 1 inhibitors and uses thereofENZO THERAPEUTICS INC·Filed 2018·Granted Jan 1, 2019·4 cites·18 claims
- 0495US9974758B2Sphingosine kinase type 1 inhibitors and uses thereofENZO THERAPEUTICS INC·Filed 2016·Granted May 22, 2018·6 cites·12 claims
- 0593US8372888B2Sphingosine kinase type 1 inhibitors, compositions and processes for using sameENZO THERAPEUTICS INC·Filed 2009·Granted Feb 12, 2013·30 cites·5 claims
- 0688US5958681ABranch migration of nucleotidesENZO THERAPEUTICS INC·Filed 1995·Granted Sep 28, 1999·101 cites·116 claims
- 0786US10723797B2Methods for treating psoriasisENZO THERAPEUTICS INC·Filed 2019·Granted Jul 28, 2020·1 cites·4 claims
- 0884US9421257B2Methods for modulating Th1/Th2 cell balance by increasing leptin activityENZO THERAPEUTICS INC·Filed 2015·Granted Aug 23, 2016·3 cites·14 claims
- 0982US7863240B2Methods and uses of leptin in hepatocellular carcinomaENZO THERAPEUTICS INC·Filed 2004·Granted Jan 4, 2011·12 cites·4 claims
- 1077US11737992B2Sphingosine kinase Type 1 inhibitors and uses thereofENZO THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·0 cites·10 claims
- 1173US10945971B2Sphingosine kinase type 1 inhibitors and uses thereofENZO THERAPEUTICS INC·Filed 2020·Granted Mar 16, 2021·0 cites·20 claims
- 1273US10624863B2Sphingosine kinase type 1 inhibitors and uses thereofENZO THERAPEUTICS INC·Filed 2019·Granted Apr 21, 2020·0 cites·10 claims
- 1372US2020331997A1Methods for treating psoriasisENZO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1469US10639324B2Glucocerebroside treatment of diseaseENZO THERAPEUTICS INC·Filed 2018·Granted May 5, 2020·0 cites·22 claims
- 1567US2021260100A1Glucocerebroside treatment of diseaseENZO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1666US2009263895A1Cell line for producing a non-retroviral vectorENZO THERAPEUTICS INC·Filed 2008·Application pending·0 cites
- 1763US7816130B2Retroviral vectors expressing exogenous gene or exogenous nucleic acid sequencesENZO THERAPEUTICS INC·Filed 2003·Granted Oct 19, 2010·0 cites·17 claims
- 1863US2020281961A1Glucocerebroside treatment of diseaseENZO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1962US2018037648A1Methods for treating melanomaENZO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2060US2018036326A1Method for treating hivENZO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2157US8367822B2Compositions and methods for bone formation and remodelingENZO THERAPEUTICS INC·Filed 2006·Granted Feb 5, 2013·0 cites·17 claims
- 2257US2017042921A1Method for treating hivENZO THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2355US8012456B2Biological models capable of exhibiting secondary disease manifestations and useful for developing therapeutic drugs, diagnostic products and therapeutic or diagnostic procedures, methods of using same, and cells, tissues and organs derived therefromENZO THERAPEUTICS INC·Filed 2001·Granted Sep 6, 2011·2 cites·2 claims
- 2455US7494806B1Retroviral vectors expressing exogenous gene or exogenous nucleic acid sequencesENZO THERAPEUTICS INC·Filed 1998·Granted Feb 24, 2009·7 cites·22 claims
- 2554US2004171526A1Regulation of immune responses by manipulation of intermediary metabolite levelsENZO THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 2654US2004171528A1Regulation of immune responses by manipulation of intermediary metabolite levelsENZO THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 2754US2018042959A1Glucocerebroside treatment of diseaseENZO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2854US2004171527A1Regulation of immune responses by manipulation of intermediary metabolite levelsENZO THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 2951US9907810B1Glucocerebroside treatment of liver disordersENZO THERAPEUTICS INC·Filed 2017·Granted Mar 6, 2018·0 cites·16 claims
- 3051US6358685B1Nucleic acid displacer compositions and cells comprising sameENZO THERAPEUTICS INC·Filed 1999·Granted Mar 19, 2002·10 cites·64 claims
- 3150US2003170258A1Novel processes implementing selective immune down regulation (SIDR)ENZO THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 3250US2005053926A1Nucleic Acid displacer compositions and cells comprising sameENZO THERAPEUTICS INC·Filed 2001·Application pending·0 cites
- 3347US2004023909A1Process for preventing or reducing undesirable immunological effects to infectious agents in subjectsENZO THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 3447US2004022768A1Process useful for producing selective immune down regulation (SIDR) in subjects, including adult subjects to artificially expressed gene, gene delivery systems, infectious agents, and non-cellular immunogenic components, and processes for producing immunological tolerance in subjets using SIDRENZO THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 3545US2007037284A1Vectors for expressing exogenous gene or exogenous nucleic acid sequencesENZO THERAPEUTICS INC·Filed 2005·Application pending·0 cites
- 3636US2006183228A1Viral vectors with surface or envelope componentsENZO THERAPEUTICS INC·Filed 2005·Application pending·0 cites
- 3733US7439060B1Independent helper virus packaging cell line for propagating viral vectorsENZO THERAPEUTICS INC·Filed 1998·Granted Oct 21, 2008·0 cites·27 claims
- 3823US7713528B1Method for in vivo delivery of active compounds using reagent conjugateENZO THERAPEUTICS INC·Filed 1995·Granted May 11, 2010·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when ENZO THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →